Results 41 to 50 of about 5,782,005 (384)

The 3' to 5' exoribonuclease DIS3: from structure and mechanisms to biological functions and role in human disease [PDF]

, 2015
DIS3 is a conserved exoribonuclease and catalytic subunit of the exosome, a protein complex involved in the 3’ to 5’ degradation and processing of both nuclear and cytoplasmic RNA species.
Carazo-Salas, Drach, Kinoshita, Lim, Noguchi, Ohkura, Sazer, Suzuki   +7 more
core   +2 more sources

Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.

Cancer Research, 2016
Multiple myeloma cells secrete more disulfide bond-rich proteins than any other mammalian cell. Thus, inhibition of protein disulfide isomerases (PDI) required for protein folding in the endoplasmic reticulum (ER) should increase ER stress beyond repair ...
S. Vatolin, James G. Phillips, B. Jha, Shravya Govindgari, Jennifer Hu, D. Grabowski, Yvonne Parker, D. Lindner, F. Zhong, C. Distelhorst, Mitchell R. Smith, C. Cotta, Yan Xu, S. Chilakala, Rebecca R Kuang, Samantha Tall, F. Reu   +16 more
semanticscholar   +1 more source

Oxo-aglaiastatin-mediated inhibition of translation initiation [PDF]

, 2019
We thank Dr. Elias George (McGill University) for the kind gift of Pgp-1-expressing HeLa cells. RIM was supported by a doctoral fellowship from the Cole Foundation.
Brown, Lauren E., Cencic, Regina, Chu, Jennifer, Devine, William G., Maiga, Rayelle Itoua, Pelletier, Jerry, Porco, John A., Sebag, Michael, Waller, Daniel D., Zhang, Wenhan   +9 more
core   +2 more sources

Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis

Scientific Reports, 2017
Reelin is an extracellular matrix protein that is crucial for neuron migration, adhesion, and positioning. We examined the expression of Reelin in a large cohort of multiple myeloma patients recorded in Gene Expression Omnibus (GEO) database and used ...
Xiaodan Qin, Liang Lin, Li-zhen Cao, Xinwei Zhang, Xiao Song, Jie Hao, Yan Zhang, Risheng Wei, Xiaojun Huang, Jin Lu, Q. Ge   +10 more
semanticscholar   +1 more source

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Blood Cancer Journal, 2020
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk ...
M. Mateos, Shaji K. Kumar, M. Dimopoulos, V. González-Calle, E. Kastritis, R. Hájek, C. F. de Larrea, Gareth J. Morgan, G. Merlini, H. Goldschmidt, C. Geraldes, A. Gozzetti, C. Kyriakou, L. Garderet, M. Hansson, E. Zamagni, D. Fantl, X. Leleu, Byung-Su Kim, G. Esteves, H. Ludwig, S. Usmani, C. Min, M. Qi, J. Ukropec, Brendan M. Weiss, S. Rajkumar, B. Durie, J. San-Miguel   +28 more
semanticscholar   +1 more source

MAGE-C1 gene and mage-c1 protein expression comparison in primary multiple myeloma patients

Онкогематология, 2022
Background. Nowadays, hematology is a dynamically developing science due to the in-depth study of the molecular mechanisms of a particular disease. A better understanding of oncohematological diseases biology makes it possible to synthesize new targeted ...
E. A. Makunina, L. P. Mendeleeva, V. L. Surin, M. V. Soloviev, M. V. Firsova, A. M. Kovrigina, A. A. Sherstnev, I. V. Gal’tseva, Y. O. Davydova, S. M. Kulikov   +9 more
doaj   +1 more source

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. [PDF]

, 2010
The HOX genes encode a family of transcription factors that are dysregulated in several malignancies and have been implicated in oncogenesis and cancer cell survival.
Daniels, TR, Morgan, R, Neacato, II, Pandha, HS, Penichet, ML, Rodríguez, JA   +5 more
core   +1 more source

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica, 2012
Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling, Edwin K. K. Lau, Ammira Al-Shabeeb, Angela Nikolic, Albert Catalano, Harry Iland, Noemi Horvath, P. Joy Ho, Simon Harrison, Shaun Fleming, Douglas E. Joshua, John D. Allen   +11 more
doaj   +1 more source

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma [PDF]

, 2019
Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in ...
Allegra A., Allegra A. G., Di Salvo E., Gangemi S., Innao V., Musolino C., Pugliese M., Ventura-Spagnolo E.   +7 more
core   +1 more source

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Journal of Immunotherapy for Cancer, 2015
BackgroundMultiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require multi-faceted approaches incorporating
Weiqing Jing, J. Gershan, James J. Weber, Dominique Tlomak, L. McOlash, C. Sabatos-Peyton, Bryon D. Johnson   +6 more
semanticscholar   +1 more source